Printer Friendly

Amylin Pharmaceuticals Announces Public Offering of Common Stock.

Amylin Pharmaceuticals, Inc. today announced a public offering of 9.2 million shares of common stock at a price of $16.60 per share, the volume-weighted average price of the common stock on January 16, 2003. The underwriters have a 30-day option to purchase up to 1.342 million additional shares of common stock from the company solely to cover over-allotments.

Goldman, Sachs & Co. is acting as book running and joint lead manager for the offering. Other joint lead managers of the offering are Lehman Brothers, Morgan Stanley and Banc of America Securities LLC. Fortis Securities Inc. is acting as co-manager for the offering.

Copies of the final prospectus supplement may be obtained from the Prospectus Departments of Goldman, Sachs & Co. (85 Broad Street, New York, New York 10004, phone 212-902-1171, fax 212-902-9316), Lehman Brothers (Lehman Brothers c/o ADP Financial Services Prospectus Fulfillment, 1155 Long Island Avenue, Edgewood, NY 11717, phone 631-254-7106, fax 631-254-7268), Morgan Stanley & Co. Incorporated (1585 Broadway, New York, New York 10036, phone 212-761-6775, fax 212-761-0211) and Banc of America Securities LLC (Prospectus Department, 600 Montgomery Street, 6th Floor, San Francisco, California 94111, phone 415-627-2220, fax 415-913-5567).

This announcement is neither an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. A registration statement relating to these securities has been filed with and has been declared effective by the Securities and Exchange Commission. The Common Stock is being offered in connection with the distribution by the issuer and represents a new financing.

Amylin Pharmaceuticals is engaged in the discovery, development and commercialization of potential drug candidates for the treatment of diabetes and other metabolic disorders.

CONTACT: Mark G. Foletta, Vice President of Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., +1-858-552-2200

Web site:
COPYRIGHT 2003 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:Jan 17, 2003
Previous Article:American Pharmaceutical Partners Announces FDA Grants Fast Track Designation for ABI-007 for Metastatic Breast Cancer.
Next Article:Westport Appoints Carter Mathies to Lead New Division.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters